Get started
Author

Maren Darsow

Observed names: M Darsow, M. Darsow, M., Darsow
Institution: Luisenkrankenhaus
ORCID: 0000-0001-9782-6738
Observed ORCID: 0000-0001-9782-6738
OpenAlex ID: A5002053095
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
2022 · C.E. Geyer, J.E. Garber, et al. · Annals of Oncology · 480
PDF
Long-Term Morbidity Following Axillary Dissection in Breast Cancer Patients – Clinical Assessment, Significance for Life Quality and the Impact of Demographic, Oncologic and Therapeutic Factors
2000 · Thorsten Kuehn, Wolfgang Klauss, et al. · Breast Cancer Research and Treatment · 230
The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer
2020 · Ulrike Nitz, Oleg Gluz, et al. · Therapeutic Advances in Medical Oncology · 44
PDF
Breast-Conserving Treatment of Breast Cancer – Oncological and Reconstructive Aspects
2008 · Stefan Krämer, Maren Darsow, et al. · Gyn�kologisch-geburtshilfliche Rundschau · 26
Autologous and Alloplastic Breast Reconstruction – Overview of Techniques, Indications and Results
2008 · Mahdi Rezai, Maren Darsow, et al. · Gyn�kologisch-geburtshilfliche Rundschau · 23
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial
2023 · O. Gluz, S. Kuemmel, et al. · Annals of Oncology · 20
PDF
Abstract GS4-03: Neoadjuvant nab-paclitaxel weekly versus dose-dense paclitaxel followed by dose-dense EC in high risk HR+/HER2- early BC by: Results from the neoadjuvant part of ADAPT HR+/HER2- trial
2021 · Sherko Kuemmel, Oleg Gluz, et al. · Cancer Research · 12
Abstract GS4-04: Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2- trial
2021 · Nadia Harbeck, Oleg Gluz, et al. · Cancer Research · 12
Abstract RF2-02: Pooled analysis of the BrighTNess, CALGB 40603 (Alliance), and GeparSixto clinical trials identifies the impact of neoadjuvant carboplatin on pCR and survival in early-stage triple-negative breast cancer
2026 · B. M. Felsheim, V. Nekljudova, et al. · Clinical Cancer Research · 6
Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial.
2021 · Oleg Gluz, Ulrike Nitz, et al. · Journal of Clinical Oncology · 6
Abstract RF2-01: Prognostic Markers in Residual Tumors after neoadjuvant chemotherapy (NACT) for Early Triple-negative Breast Cancer (TNBC) - a Pooled Analysis from nine Neoadjuvant GBG/AGO-B Trials
2026 · J. Holtschmidt, A. Schneeweiss, et al. · Clinical Cancer Research · 3
Tumor-Adapted Reduction Mammoplasty in Oncoplastic Breast Surgery
2007 · Mahdi Rezai, Maren Darsow · Breast Care · 3
Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al. · Clinical Cancer Research · 2
Efficiency of controlled cryotherapy in prevention of chemotherapy induced peripheral neuropathy (CIPN)
2019 · T. Schaper, M. Rezai, et al. · Annals of Oncology · 2
Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPT
2026 · Michael Braun, Oleg Gluz, et al. · Breast Care · 1
PDF
Patient outcomes in WSG-ADAPT according to NATALEE and MonarchE risk criteria.
2025 · Oleg Gluz, Michael Wilhelm Braun, et al. · Journal of Clinical Oncology · 1
PDF
Die prophylaktische Nutzung der Hilotherapy® (gradgenaues Thermoheilverfahren) vermeidet die Entwicklung von schwerwiegender CIPN in der Chemotherapie
2020 · T Schaper, M Rezai, et al. · Geburtshilfe und Frauenheilkunde · 1
Role of neoadjuvant versus adjuvant chemotherapy, dose density, and treatment schedule in biologically high-risk HR+/HER2- breast cancer: A pooled analysis of the WSG ADAPT-HR+/HER2- and PlanB trials.
2026 · Oleg Gluz, Sherko Kuemmel, et al. · Journal of Clinical Oncology
PDF
78P Desmocollin 2 as a predictive marker for the development of distant metastasis (mets) in Breast Cancer (BC)
2026 · E. Laakmann, L. Oliveira-Ferrer, et al. · ESMO Open
PDF
Abstract PS4-08-07: Predicting response and survival after neoadjuvant systemic treatment with on-treatment biopsies
2026 · C. Denkert, A. Schneeweiss, et al. · Clinical Cancer Research
Supplementary Material for: Refining risk assessment for adjuvant CDK4/6 inhibitors beyond trial inclusion criteria: integrating recurrence score and endocrine responsiveness according to ADAPT
2026 · karger, figshare admin, M., Braun, et al. · Figshare
Supplementary Figure S1 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Table S6 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Table S4 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
PDF
Supplementary Figure S2 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025 · Thomas E. Mürdter, Werner Schroth, et al.
Works count: 50
Citation count: 871
H-index: 8
I10-index: 8
Year
Topic
Type